All In Biotech

NDA 208400 · Azurity

Xatmep

Methotrexate Sodium · Oral · Folate Analog Metabolic Inhibitor

Orphan

Last checked: Nov 20, 2026Latest source record: May 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Apr 25, 2017

Approved uses

2

Original approval plus efficacy supplements

Registered trials

2,087

570 Phase 3, 211 recruiting

FAERS reports

415,567

315,085 serious, 34,393 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SEVERE TOXIC REACTIONS, INCLUDING EMBRYO-FETAL TOXICITY, AND RISK OF MEDICATION ERRORS Methotrexate can cause the following severe or fatal adverse reactions. Monitor closely and modify dose or discontinue methotrexate as appropriate. o Bone marrow suppression [see Warnings and Precautions ( 5.1 )] o Serious infections [see Warnings and Precautions ( 5.2 )] o Renal toxicity and increased toxicity with renal impairment [see Warnings and Precautions ( 5.3 )] o Gastrointestinal toxicity [see Warnings and Precautions ( 5.4 )] o Hepatic toxicity [see Warnings and Precautions ( 5.5 )] o Pulmonary toxicity [see Warnings and Precautions ( 5.6 )] o Hypersensitivity and dermatologic reactions [see Warnings and Precautions ( 5.7 )] Methotrexate can cause embryo-fetal toxicity, including fetal death. Use in pJIA is contraindicated in pregnancy. Consider the benefits and risks of XATMEP and...

What it is approved for

From the label in effect May 28, 2026.

XATMEP is a folate analog metabolic inhibitor indicated for the: Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as a component of a combination chemotherapy maintenance regimen ( 1.1 ). Management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who are intolerant of or had an inadequate response to first-line therapy ( 1.2 ). 1.1 Acute Lymphoblastic Leukemia XATMEP is indicated for the treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a multi-phase, combination chemotherapy maintenance regimen. 1.2 Polyarticular Juvenile Idiopathic Arthritis XATMEP is indicated in the management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs).

Mechanism: Methotrexate inhibits dihydrofolic acid reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of one-carbon groups in the synthesis of purine nucleotides and thymidylate. Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication. Actively proliferating tissues such as malignant cells, bone marrow, fetal cells, buccal and intestinal mucosa, and cells of the urinary bladder are in general more sensitive to this effect of methotrexate. The mechanism of action in pJIA is unknown; it may affect immune...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • XATMEP · METHOTREXATE SODIUM EQ 2.5MG BASE/ML · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Methotrexate" as an intervention, any sponsor and status, largest first.

All 2,087 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective75,830
  • rheumatoid arthritis38,596
  • arthralgia36,779
  • pain35,909
  • off label use35,261
  • fatigue29,599
  • nausea24,360
  • joint swelling22,621
  • headache21,285
  • rash20,347
  • condition aggravated20,228
  • drug intolerance20,017

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20045,129
20055,083
20064,969
20077,782
20088,995
20099,160
20109,678
201110,610
201214,953
201316,975
201416,960
201520,301
201621,746
201722,400
201831,889
201932,100
202039,618
202126,418
202229,158
202326,798
202423,076
202520,037
202611,723

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xatmep (Methotrexate)

2024 spending

$246K

Beneficiaries

84

238 claims

Per beneficiary

$2,934

$19.76 per unit

View as table
YearSpending
2020$91,272
2021$119,158
2022$152,175
2023$248,445
2024$246,466

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,151 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.